• Vinayak Kohli
    Vinayak Kohli
    • over 9 years ago
    • Practical Guidance Journal
    • pa

    Drafting and Negotiating Effective Cloud Computing Agreements

    By: Michael R. Overly , Foley & Lardner LLP. LEXIS PRACTICE ADVISOR RESEARCH PATH: IntellectualProperty & Technology > Software & Information Technology >Cloud Computing > Practice Notes > Drafting and Negotiating EffectiveCloud...
  • Vinayak Kohli
    Vinayak Kohli
    • over 7 years ago
    • Practical Guidance Journal
    • pa

    In-House Counsel’s Role In Cybersecurity & Data Protection

    THE CONDUCTOR CANNOT HOPE TO KNOW EVERYTHING about each section of the orchestra, (e.g., what strings, woodwinds, brass, and percussion must do in order to play their part). However, each section (and subsection) has its own chair who can determine that...
  • Vinayak Kohli
    Vinayak Kohli
    • over 8 years ago
    • Practical Guidance Journal
    • pa

    Strategies and Opportunities in an America Invents Act World – Choices of Venue

    By: Ethan Horwitz , Carlton Fields. TODAY, BOTH PATENT OWNERS AND ACCUSED INFRINGERS have multiple choices of venues in which to litigate the validity of a patent. There is the historic option of a patent infringement case in the federal courts. Increasingly...
  • Vinayak Kohli
    Vinayak Kohli
    • over 6 years ago
    • Practical Guidance Journal
    • pa

    Biosimilars and The Biologics Price Competition and Innovation Act (BPCIA)

    By: Michael Furrow , DLA Piper, and Whitney Meier , Venable LLP The Biologics Price Competition and Innovation Act (BPCIA) provides an abbreviated pathway for companies to bring biologic drugs to market that are biosimilar to previously approved branded...
  • Vinayak Kohli
    Vinayak Kohli
    • over 6 years ago
    • Practical Guidance Journal
    • pa

    Pharmaceutical Patent Litigation Strategies

    By: Jeffrey Alan Hovden, Robins Kaplan LLP This article discusses strategies that counsel for brand-name and generic drug companies may employ in pharmaceutical patent litigation under the Drug Price Competition and Patent Term Restoration Act of 1984...
<>